Can people with type 1 diabetes use Wegovy?
People with type 1 diabetes should not use Wegovy to manage their diabetes. Semaglutide (the active ingredient) is not a substitute for insulin and is not indicated for type 1 diabetes or diabetic ketoacidosis. UK product information and clinical guidance state that GLP-1 medicines like semaglutide must not replace insulin in insulin-dependent patients, and reducing or stopping insulin when starting a GLP-1 can trigger dangerous ketoacidosis. While the Wegovy patient leaflet warns that low blood sugar can occur when semaglutide is used with insulin or sulfonylureas, this does not change the fact that insulin remains essential in type 1 diabetes. In the UK, Wegovy is licensed for weight management, not for treating type 1 diabetes. Any consideration of weight treatment in someone with type 1 diabetes must be supervised by a specialist team.
- Wegovy is not a treatment for type 1 diabetes and must not replace insulin.
- UK guidance warns of ketoacidosis if insulin is reduced or stopped when starting GLP-1 drugs in insulin-dependent patients.
- The patient leaflet notes Wegovy can cause hypos when used with insulin—highlighting the need for medical supervision in anyone with diabetes.
- Wegovy is licensed for weight management, not to treat type 1 diabetes; specialist input is essential for people with type 1 diabetes considering weight treatment.